Efforts Initiated to Conduct First FDA Phase 1 Trial for ALS

Huffington Post—July 30, 2015

The Huffington Post reports that Hospital for Special Surgery and Tikun Olam, an Israeli medical marijuana company have begun a clinical trial to test the effectiveness of certain high cannabidiol strains of the drug on ALS, a degenerative neurological condition also known as Lou Gehrig’s disease.

The initiative is being led by Dale J. Lange, MD, Chairman of Neurology and Neurologist-in-Chief at Hospital for Special Surgery, who would write the protocols for the trial. "I am very interested in looking into the effects of high CBD/low TCH in patients with ALS and UMN predominant motor system disease," said Dr. Lange. "We have more than 20 years of experience conducting clinical therapeutic trials for patients with neuromuscular disorders at all phases of drug development. This would be a phase I trial assessing safety and data gathering for endpoints."

To read more visit www.huffingtonpost.com.